24.43

1.88% 0.45

After Hours: 24.47 0.04 +0.16%

Pulse Biosciences Inc (PLSE)

Overview News Price History Option Chain Financials Discussions Forecast

Pulse Biosciences Inc stock is traded at $24.43, with a volume of 188.67K. It is up +1.88% in the last 24 hours and up +10.54% over the past month. Pulse Biosciences Inc is a novel bioelectric medicine company committed to health innovation using its patented Nano-Pulse Stimulation technology, a revolutionary energy modality that delivers nanosecond-duration pulses of electrical energy, each less than a millionth of a second long, to non-thermally clear targeted cells while sparing adjacent noncellular tissue. NPS technology, also referred to as Nanosecond Pulsed Field Ablation (nsPFA) technology delivers nanosecond pulses of electrical energy to nonthermally clear cells while sparing adjacent noncellular tissue.

Previous Close:

$23.98

Open:

$24.32

24h Volume:

188.67K

Relative Volume:

0.56

Market Cap:

$1.66B

Revenue:

$350.00K

Net Income/Loss:

$-72.78M

P/E Ratio:

-22.62

EPS:

-1.08

Net Cash Flow:

$-54.46M

1W Performance:

+24.36%

1M Performance:

+10.54%

6M Performance:

+41.62%

1Y Performance:

+33.72%

1-Day Range:

$22.29

$24.84

1-Week Range:

$19.75

$24.84

52-Week Range:

$12.56

$26.30

Pulse Biosciences Inc Stock (PLSE) Company Profile

Name

Pulse Biosciences Inc

Sector

Healthcare (1109)

Industry

Medical Instruments & Supplies (58)

Phone

510-906-4600

Address

3957 POINT EDEN WAY, HAYWARD, CA

Employee

116

Twitter

@PulseBioNPS

Next Earnings Date

2026-05-14

Latest SEC Filings

PLSE's Discussions on Twitter

Compare PLSE vs ISRG, BDX, MDLN, ALC, RMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
PLSE Pulse Biosciences Inc	24.43	1.63B	350.00K	-72.78M	-54.46M	-1.08
ISRG Intuitive Surgical Inc	483.62	160.28B	10.06B	2.88B	2.49B	7.876
BDX Becton Dickinson Co	155.65	44.57B	21.92B	1.76B	2.63B	6.1223
MDLN Medline Inc	47.16	38.56B	28.43B	1.16B	1.26B	1.4457
ALC Alcon Inc	76.43	37.93B	10.40B	980.00M	1.61B	1.9749
RMD Resmed Inc	222.04	32.23B	5.40B	1.49B	1.78B	10.12

Pulse Biosciences Inc Stock (PLSE) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-30-26	Initiated	Mizuho	Outperform
Jul-07-25	Initiated	Oppenheimer	Outperform
Jul-27-21	Initiated	Stephens	Overweight
Mar-11-21	Initiated	Maxim Group	Buy
Jan-26-21	Reiterated	H.C. Wainwright	Buy
May-12-20	Upgrade	H.C. Wainwright	Neutral → Buy
Feb-14-20	Downgrade	H.C. Wainwright	Buy → Neutral
Feb-25-19	Initiated	H.C. Wainwright	Buy

View All

Pulse Biosciences Inc Stock (PLSE) Latest News

Apr 20, 2026

Pulse Biosciences' nPulse Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting - Investing News Network

Apr 20, 2026

Pulse Biosciences (PLSE) to Showcase Innovations at Heart Rhythm Society 2026 Meeting - GuruFocus

Apr 20, 2026

Pulse Biosciences Starts US Trial for Cardiac Catheter System - HarianBasis.co

Apr 20, 2026

Pulse Biosciences (PLSE) Enrolls Its First Patients in a Pivotal Atrial Fibrillation Trial - Insider Monkey

Apr 20, 2026

Pulse Biosciences’ nPulse™ Technology to be Featured at the Heart Rhythm Society 2026 Annual Meeting - Business Wire

Apr 20, 2026

Apr 19, 2026

Total debt per share of Pulse Biosciences, Inc. – FWB:6L8 - TradingView

Apr 19, 2026

Apr 18, 2026

Pulse (PLSE) Stock: Is It Moving in a Trend (Breakout Watch) 2026-04-18Asset Allocation - Xã Vĩnh Công

Apr 18, 2026

Apr 17, 2026

Pulse Biosciences (NASDAQ:PLSE) Trading 10.1% HigherHere's Why - MarketBeat

Apr 17, 2026

Pulse Biosciences to Host Analyst Event on April 25, 2026 - The Joplin Globe

Apr 17, 2026

PLSE Stock Price, Quote & Chart | PULSE BIOSCIENCES INC (NASDAQ:PLSE) - ChartMill

Apr 17, 2026

Apr 16, 2026

Pulse Biosciences Targets Thyroid Nodules With New Device Study, Eyeing a Minimally Invasive Niche - TipRanks

Apr 16, 2026

Pulse Biosciences Updates 2026 Cardiac Ablation Strategy - TipRanks

Apr 16, 2026

Pulse Biosciences posts updated investor deck with pivotal nsPFA cardiac study details - TradingView

Apr 16, 2026

Pulse Biosciences (PLSE) updates investor deck with 2026 clinical goals - Stock Titan

Apr 16, 2026

Apr 15, 2026

Trading Systems Reacting to (PLSE) Volatility - Stock Traders Daily

Apr 15, 2026

Apr 13, 2026

Mizuho Securities Maintains Pulse Biosciences(PLSE.US) With Buy Rating, Maintains Target Price $30 - 富途牛牛

Apr 13, 2026

Income Plays: Does Pulse Biosciences Inc have strong fundamentalsPortfolio Update Summary & Reliable Price Breakout Signals - baoquankhu1.vn

Apr 13, 2026

Pulse Biosciences Initiates Patient Enrollment in NANOPULSE-AF Study - Yahoo Finance

Apr 13, 2026

Is Pulse Biosciences’ New Leadership Structure Reframing the PLSE Cardiac Therapy Commercialization Story? - Sahm

Apr 13, 2026

Apr 12, 2026

Pulse Biosciences Inc at TD Cowen Healthcare Conference Transcript - GuruFocus

Apr 12, 2026

Can Pulse Biosciences’ (PLSE) New AF Study and C-Suite Hires Reframe Its PFA Strategy? - Yahoo Finance

Apr 12, 2026

Apr 11, 2026

Q4 2025 Pulse Biosciences Inc Earnings Call Transcript - GuruFocus

Apr 11, 2026

Apr 10, 2026

Pulse Biosciences hires Liane Teplitsky as COO - MedTech Dive

Apr 10, 2026

Apr 09, 2026

Pulse Biosciences names Liane Teplitsky as chief operating officer By Investing.com - Investing.com Australia

Apr 09, 2026